Monoclonal autoantibodies such as Dupilumab (Dupixent®) are new, highly effective drugs that prevent signal molecules from binding to cells of the nasal mucosa. This can stop damage to the nasal mucosa and the formation of polyps. Due to their effectiveness at the cell level and within the immune system, the treatment requires special attention.
KOPFZENTRUM offers with the care lump sum all achievements, which are not contained in the service catalog of the legal cashes, in our conviction however absolutely necessary for the company of the therapy with monoclonal antibodies.
These services correspond to the medical fee schedule and are offered by KOPFZENTRUM at a package price of 60 Euro. This care flat rate is only charged once per patient.